Philippe Legenne

963 total citations
29 papers, 516 citations indexed

About

Philippe Legenne is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Philippe Legenne has authored 29 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Philippe Legenne's work include Lung Cancer Treatments and Mutations (7 papers), Peptidase Inhibition and Analysis (6 papers) and Melanoma and MAPK Pathways (5 papers). Philippe Legenne is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Peptidase Inhibition and Analysis (6 papers) and Melanoma and MAPK Pathways (5 papers). Philippe Legenne collaborates with scholars based in United Kingdom, United States and France. Philippe Legenne's co-authors include Stephen Lane, Georgina V. Long, Michael A. Davies, Caroline Robert, Dirk Schadendorf, Paul Nathan, Antoni Ribas, Keith T. Flaherty, Jean‐Jacques Grob and Carmen Mak and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Philippe Legenne

28 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Legenne United Kingdom	8	362	287	119	78	53	29	516
Timothy T. C. Yip China	11	250 0.7×	229 0.8×	48 0.4×	85 1.1×	40 0.8×	18	561
Pratik Chandrani India	13	203 0.6×	262 0.9×	237 2.0×	35 0.4×	39 0.7×	53	581
C. Papadimitriou Greece	9	241 0.7×	203 0.7×	65 0.5×	24 0.3×	95 1.8×	16	513
Weiwei Shi China	11	128 0.4×	198 0.7×	81 0.7×	9 0.1×	43 0.8×	21	450
Christiane Schewe Germany	13	204 0.6×	187 0.7×	84 0.7×	41 0.5×	153 2.9×	18	571
Grace Tin‐Yun Chung Hong Kong	10	298 0.8×	305 1.1×	33 0.3×	37 0.5×	49 0.9×	13	618
Klaudia Szymonowicz United States	8	126 0.3×	232 0.8×	95 0.8×	26 0.3×	153 2.9×	9	483
Rene Quevedo Canada	9	182 0.5×	249 0.9×	45 0.4×	10 0.1×	22 0.4×	15	503
C Dionet France	9	211 0.6×	159 0.6×	91 0.8×	14 0.2×	35 0.7×	26	424
Tanuja Teni India	15	158 0.4×	280 1.0×	67 0.6×	105 1.3×	59 1.1×	31	517

Countries citing papers authored by Philippe Legenne

Since Specialization

Citations

This map shows the geographic impact of Philippe Legenne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Legenne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Legenne more than expected).

Fields of papers citing papers by Philippe Legenne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Legenne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Legenne. The network helps show where Philippe Legenne may publish in the future.

Co-authorship network of co-authors of Philippe Legenne

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Legenne. A scholar is included among the top collaborators of Philippe Legenne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Legenne. Philippe Legenne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stumpp, Michael T., Vladimir Kirkin, Michael P. Sanderson, Keith M. Dawson, & Philippe Legenne. (2025). A Decade of Clinical Experience with DARPins in Oncology and Virology: A Systematic Review. medRxiv. 2 indexed citations

Steeghs, Neeltje, Carlos Gomez‐Roca, Eelke Gort, et al.. (2024). Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2573–2573. 2 indexed citations

Knop, Stefan, Norbert Grząśko, Karolin Trautmann‐Grill, et al.. (2024). A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. SHILAP Revista de lepidopterología. 5(5). 940–950. 4 indexed citations

Jongen‐Lavrencic, Mojca, Thomas Pabst, Pierre Bories, et al.. (2024). MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study. Blood. 144(Supplement 1). 2881–2881. 4 indexed citations

Stavropoulou, Vaia, Alison Ribeiro, Hilde De Winter, et al.. (2024). 612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin. Regular and Young Investigator Award Abstracts. A704–A704. 1 indexed citations

Zitt, Christof, Pierre Fustier, Vaia Stavropoulou, et al.. (2023). Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study. British Journal of Clinical Pharmacology. 89(7). 2295–2303. 3 indexed citations

Gomez‐Roca, Carlos, Neeltje Steeghs, Eelke Gort, et al.. (2023). Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2584–2584. 3 indexed citations

Winter, Hilde De, Vaia Stavropoulou, Paul Baverel, et al.. (2022). 1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors. A1534–A1534. 1 indexed citations

Fischer, Stefanie, Thorsten Oliver Götze, Aurelius Omlin, et al.. (2022). A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precision Oncology. 6(6). e2200006–e2200006. 5 indexed citations

10.

Jeger, Simone, Oliver Schönborn‐Kellenberger, Hilde De Winter, et al.. (2021). 170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors. Annals of Oncology. 32. S1456–S1457. 1 indexed citations

11.

Atkinson, Victoria, Shahneen Sandhu, Geke A.P. Hospers, et al.. (2020). Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research. 30(3). 261–267. 25 indexed citations

12.

Long, Georgina V., Jean‐Jacques Grob, Paul Nathan, et al.. (2016). Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. The Lancet Oncology. 17(12). 1743–1754. 212 indexed citations

13.

Kerklaan, Bojana Milojkovic, Martijn P. Lolkema, Lot A. Devriese, et al.. (2015). Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British Journal of Cancer. 113(5). 706–715. 19 indexed citations

14.

Atkinson, Victoria, Johannes V. van Thienen, Grant A. McArthur, et al.. (2015). 3337 Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study. European Journal of Cancer. 51. S677–S678. 2 indexed citations

15.

Harrington, Kevin J., Stéphane Temam, Anil D′Cruz, et al.. (2014). Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 32(15_suppl). 6005–6005. 19 indexed citations

16.

Spigel, David R., et al.. (2013). Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study. Clinical Lung Cancer. 14(4). 356–363. 29 indexed citations

17.

Kerklaan, Bojana Milojkovic, Martijn P. Lolkema, Lot A. Devriese, et al.. (2013). Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2536–2536. 5 indexed citations

18.

Harrington, Kevin J., Martin Robinson, Éva Remenár, et al.. (2012). Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease. European Journal of Cancer. 49(7). 1609–1618. 89 indexed citations

19.

Rose, Peter G., et al.. (2010). An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecologic Oncology. 120(1). 38–42. 6 indexed citations

20.

Schwartz, Peter E., B.J. Monk, Diane Provencher, et al.. (2008). An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: First stage results. Journal of Clinical Oncology. 26(15_suppl). 16518–16518. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact